Cargando…
2160. Emergence of INDEL Mutations in KPC-2: Insights into Ceftazidime-Avibactam and Imipenem-Relebactam Efficacy
BACKGROUND: Enterobacterales producing KPC-2 and KPC-3 β-lactamases (Bla) are a significant clinical threat. Ceftazidime/avibactam (CZA) and imipenem/relebactam (IMI/REL) are successful in the treatment for these infections. Unfortunately, CZA-resistant isolates are emerging as a result of amino aci...
Autores principales: | Brunetti, Florencia, Bethel, Christopher R, Sanz, María Belén, Pasterán, Fernando, Gutkind, Gabriel, Gomez, Sonia, Bonomo, Robert A, Power, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677562/ http://dx.doi.org/10.1093/ofid/ofad500.1783 |
Ejemplares similares
-
The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
por: Papp-Wallace, Krisztina M., et al.
Publicado: (2023) -
Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates
por: Rogers, Tara M, et al.
Publicado: (2023) -
Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
por: Bovo, Federica, et al.
Publicado: (2023) -
Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
por: Wang, Leilei, et al.
Publicado: (2023) -
Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
por: Nordmann, Patrice, et al.
Publicado: (2023)